Close Menu

NEW YORK – Quest Diagnostics said today it has entered an agreement to provide Catholic Health Services of Long Island with laboratory management services and reference testing.

Under the agreement, Quest will provide CHS with lab testing as well as management of lab equipment, supplies, and procurement processes. The agreement covers six CHS hospitals, a core lab, a cancer center, and an infusion center.

Financial and other terms of the deal were not disclosed.

According to Secaucus, New Jersey-based Quest, CHS has 24 percent market share on Long Island.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.